

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

-----X
:
IN RE ELIQUIS (APIXABAN) PRODUCTS :
LIABILITY LITIGATION :
:
This document relates to: ALL ACTIONS. :
:
-----X

17md2754 (DLC)
and all member and
related cases
SCHEDULING ORDER

DENISE COTE, District Judge:

As set forth in the March 7, 2017 Order and as discussed on the record at the March 17 conference, it is hereby


ORDERED that any action presently assigned to this Court -- excluding the Utts v. Bristol-Myers Squibb Co. & Pfizer Inc., 16cv5668 (DLC) action -- shall have until May 23 to file an amended complaint and to show cause in a memorandum no longer than 20 pages why the amended complaint should not be dismissed based on the analysis in the May 8 Utts Opinion.

IT IS FURTHER ORDERED that any future action transferred or reassigned to this Court shall have fourteen days following arrival on this Court's docket to file an amended complaint and to show cause in a memorandum no longer than 20 pages why the amended complaint should not be dismissed based on the analysis in the May 8 Utts Opinion.

IT IS FURTHER ORDERED that it is unlikely that the plaintiffs in any of these actions will have a further opportunity to amend.

IT IS FURTHER ORDERED that the defendants shall file a reply or replies to the plaintiffs' submissions by June 20, at which point the motions to dismiss each action will be considered fully submitted.

Dated: New York, New York
May 9, 2017



DENISE COTE
United States District Judge